Johnny Nacilla, MD
Medical Oncology · Cullman, ALNPI 1346261526
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,824 of the $23,206 with a category attached, or 89.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 1,151 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- AstraZeneca$2K
- Pfizer$1K
- Johnson & Johnson$1K
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$969
- plus $12K from 54 others
What the payments were for
- Food & beverage$20,82490%
- Education$7513%
- Other$1,6317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,206 in reported general payments places this provider in the 85th percentile of 30 medical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 93 | $1,421,848 |
| RevlimidLenalidomide | 50 | $877,393 |
| ImbruvicaIbrutinib | 58 | $865,538 |
| Lenalidomide | 50 | $578,829 |
| PomalystPomalidomide | 11 | $215,830 |
| KisqaliRibociclib Succinate | 12 | $181,286 |
| CalquenceAcalabrutinib Maleate | 11 | $175,493 |
| BrukinsaZanubrutinib | 12 | $164,985 |
| XtandiEnzalutamide | 11 | $155,121 |
| VenclextaVenetoclax | 13 | $134,248 |
| HerceptinTrastuzumab | 13 | $51,846 |
| EliquisApixaban | 56 | $38,124 |
| EpogenEpoetin Alfa | 22 | $27,069 |
| XareltoRivaroxaban | 38 | $20,682 |
| Abiraterone Acetate | 12 | $16,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $884 | $1,421,84893 claims |
| Bristol Myers SquibbRevlimid | $797 | $877,39350 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $427 | $865,53858 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $969 | $215,83011 claims |
| NovartisKisqali | $3,853 | $181,28612 claims |
| AstraZenecaCalquence | $2,003 | $175,49311 claims |
| Beigene USA, Inc.Brukinsa | $148 | $164,98512 claims |
| Astellas Pharma US IncXtandi | $138 | $155,12111 claims |
| AbbVieVenclexta | $495 | $134,24813 claims |
| PfizerEliquis, Retacrit | $1,179 | $53,72672 claims |
| AmgenEpogen | $1,171 | $27,06922 claims |
| Johnson & JohnsonXarelto | $1,173 | $20,68238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 medical oncology providers in Alabama.
Other medical oncology in Cullman
- Joelle HamiltonHomewood$361K
- Syed Abbas AliJasper$51K
- Pranitha ProdduturvarMobile$33K
- Michael GarciaJasper$23K
- John WaplesHuntsville$19K
- Susan BostickTuscaloosa$17K
- Brittany CaseDaphne$17K
- Charles LattuadaAnniston$16K
- David HintonTuscaloosa$16K
- James DaughertyFlorence$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.